UCB’S IMPRESSIVE FULL DECK (ADD; 15% UPSIDE)
27/11/20 -"After being range-bound for the most part of 2019, UCB (Add, Belgium) gained momentum in October 2019 when the company made an acquisition in the fast-growing (c.10% p.a.) myasthenia gravis/MG space ..."
Pages
53
Language
English
Published on
27/11/20
You may also be interested by these reports :
23/07/26
Despite FX headwinds, the Q2 results were ahead of the street’s expectations. The performance was driven by drugs across therapeutic areas, and the ...
22/07/26
Lonza published its 1H results, with a strong operating performance but a mixed revenue outcome. The group grew by +16% (CER) YoY, with strong FX ...
21/07/26
The Q2 sales growth was supported by a healthy showing across both segments. The management now expects full-year growth to be at the upper end of ...
21/07/26
The Q2 results exceeded expectations, aided by the strong performance of cancer and neuroscience medicines, healthy growth in immunology offerings, ...